Managing Principal Alan White to Present Poster on Harm Reduction Models for Abuse-Deterrent Opioids during PAINWeek 2017
Date: September 7, 2017
Location:Las Vegas, NV
Times:9:00 p.m. (PT) / 12:00 a.m. (ET)
Misuse/abuse of prescription opioids has been recognized as a public health crisis by the US Food and Drug Administration (FDA), and the FDA's Opioid Plan recognizes abuse-deterrent (AD) formulations of opioids as critical to mitigating opioid misuse/abuse.
Managing Principal Alan White, along with Tim Spittle (Senior Analyst, Analysis Group), Gwendolyn Niebler (Egalet US Inc.), Jeffrey Dayno (Egalet US Inc.), Colville Brown (Egalet US Inc.), and Nathaniel Katz (Analgesic Solutions) will present a poster entitled "A Harm Reduction Model to Quantify Potential Misuse/Abuse Reduction and Abuse-Related Events Avoided from Abuse-Deterrent Opioids" at PAINWeek 2017.
The presenting team used a harm reduction model-based approach to investigate the potential for reducing opioid misuse/abuse-related events by simulating, over 5 years, the replacement of non-abuse deterrent morphine formulations with morphine ADER-IMT. The model, which incorporated real-world data, suggests that replacement of non-abuse deterrent morphine with morphine ADER-IMT could lead to significant potential reductions in opioid abuse-related adverse events.
PAINWeek is the largest US pain conference for frontline clinicians with an interest in pain management.